ArticleBJU international2024
Prediction of biochemical recurrence after radical prostatectomy from primary tumour characteristics.
Article in BJU international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Correlation of intraprostatic lesional SUVmax during PSMA PET/CT and adverse pathology at radical prostatectomy.Prostate cancer and prostatic diseases · 2026Article
- Prognostic value of PSMA PET/CT-Based local staging in predicting biochemical recurrence after radical prostatectomy.European journal of nuclear medicine and molecular imaging · 2026Article
- Development and validation of an online predictive model for biochemical recurrence after radical prostatectomy in elderly patients.Frontiers in oncology · 2026Article
- Radical prostatectomy outcomes in patients with PI-RADS 5 lesions and favorable prostate cancer.World journal of urology · 2025Article
- Quantification of prostate cancer Gleason pattern 4 to predict oncological outcome.BJU international · 2025Article
- Biopsy-free radical prostatectomy: a narrative review considering rationale, limitations, and current data.Prostate international · 2025Review
- Reduced prostate cancer screening has a negative impact on stage migration: the Australian experience.BJU international · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo construct and externally calibrate a predictive model for early biochemical recurrence (BCR) after radical prostatectomy (RP) incorporating clinical and modern imaging characteristics of the primary tumour. PATIENTS AND
methodsPatients who underwent RP following multiparametric magnetic resonance imaging, prostate biopsy and prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT), from two centres in Australia and the Netherlands. The primary outcome was biochemical recurrence-free survival (BRFS), where BCR was defined as a rising PSA level of ≥0.2 ng/mL or initiation of postoperative treatment per clinician discretion. Proportional hazards models to predict time to event were developed in the Australian sample using relevant pre- and post-surgical parameters and primary tumour maximum standardised uptake value (SUV
resultsData from 846 patients were used to develop the models. Tumour SUV
conclusionTumour SUV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.